Induction and Inhibition of Cytochrome P450 and Drug-Metabolizing Enzymes by Climbazole
for determination of P450 content, aminopyrine N-demethylase and erythromycin N-demethylase activities, uridine 5Ј-phosphate (UDP)-glucuronosyl transferase levels, and immunoblot analysis. Cytosolic fractions were used for measurement of glutathione S-transferase activity. For total RNA isolation, a portion of liver was immediately flash-frozen in liquid nitrogen and stored at Ϫ80°C until use. Enzyme Assays P450 content was determined by the CO-difference spectrum of dithionite-treated microsomes (2 mg protein/ml) as described by Omura and Sato. 22) Aminopyrine and erythromycin N-demethylase activities were measured by determining formaldehyde formation according to the method of Nash. 23) Glutathione S-transferase activity against 1-chloro-2,4-dinitrobenzene was assayed spectrophotometrically according to the method of Habig and Jakoby. 24) Microsomal UDP-glucuronosyl transferase activity against pnitrophenol was determined spectrophotometrically from the disappearance of 4-nitrophenol according to the method of Tukey et al. 25) Protein concentration was estimated by the method of Lowry et al. 26) using bovine serum albumin as the standard.
Electrophoresis and Immunoblot Analysis Microsomes obtained from control and climbazole-treated rats were solubilized in sodium dodecyl sulfate (SDS) and resolved by polyacrylamide gel electrophoresis (PAGE) according to the method of Laemmli.
27) Antigenic components reactive with polyclonal antibodies raised against various P450 species were visualized with 4-chloro-1-naphthol in the presence of 0.006% (v/v) hydrogen peroxide and peroxidaselabeled anti-goat IgG in 0.05 M Na,K-phosphate buffer (pH 7.4). Semiquantification of the bands was assayed using a computer imaging analysis system (Quantity One, BIO-RAD, Hercules, CA, U.S.A.).
Total RNA Isolation Total RNA was isolated from the liver treated with climbazole by using the acid guanidine thiocyanate (GTC)-phenol-chloroform extraction according to the method of Chomczynski and Sacchi. 28) The liver from three to four rats was pooled and homogenized in a 10-bed volume of 4 M GTC containing 25 mM sodium citrate (GTC solution) (pH 7.0), 0.5% sarkosyl and 0.1 M 2-mercaptoethanol (10 ml GTC solution/100 mg of liver tissue). The RNA was extracted twice into phenol and chloroform (1 vol. phenol/0.2 vol. chloroform/1 vol. GTC solution) and precipitated with isopropanol at room temperature. The pellet was dissolved in GTC solution 0.3 ml and precipitated with isopropanol at Ϫ20°C. The resulting RNA pellet was washed with ice-cold 80% ethanol and dissolved in an appropriate volume of diethylpyrocarbonate (DEPC)-treated water. The RNA yield, purity, and integrity were determined by the absorbance at the 260/280 nm ratio (Ͼ1.6) and confirmed with 1.0% agarose/formamide gel.
Northern Blot Analysis Twenty micrograms of total RNA were denatured in 1ϫMOPS buffer (0.02 M MOPS, 0.3 M sodium acetate, 1 mM EDTA, 2.2 M formaldehyde, and 50% deionized formamide, pH 7.0) at 65°C for 10 min and then quickly chilled on ice before loading onto 1.0% agarose/formamide gel. RNA samples were stained with ethidium bromide (1.6 mg/ml), and loading efficiency was confirmed by ultraviolet fluorescence. After electrophoresis, RNA was transferred onto a nylon membrane (Hybond Nϩ, Amersham Pharmacia Biotech) for Ͼ18 h with 20ϫSSPE (3 M NaCl, 173 mM NaH 2 PO 4 · 12H 2 O, 25 mM EDTA). The replicated membrane was probed with 32 P-labeled CYP2B1 cDNA (1.25 kb, Pst1 fragment of rpcP-450pb1 cDNA, Riken, Saitama, Japan). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) cDNA was amplified by RT-PCR using the sense primer 5Ј-TCCACCACCCTGTTGCTGTA-3Ј and antisense primer 5Ј-ACCAGAGTCCATGCCATCAC-3Ј to yield a 0.45-kb fragment. RT-PCR was performed under the following conditions: 1 cycle at 60°C for 30 min, 1 cycle at 94°C for 2 min, 40 cycles at 91°C for 30 s, annealing at 62°C for 30 s, 72°C for 30 s, followed by a final extension at 72°C for 10 min according to the manufacture's instructions (TOYOBO, Osaka, Japan). For hybridization, the insert and PCR product were labeled by the random primer extension method 29) using a random primer labeling kit ( T7 QuickPrime TM Kit, Amersham Pharmacia Biotech, Buckinghamshire). The filter was prehybridized with for 2 h at 42°C in a prehybridization solution (0.5 M sodium phosphate [pH 6.5], 50% formamide, 5ϫSSC, 5ϫDenhardt's solution, 280 mg/ml sheared denatured salmon sperm DNA). The filters were then subjected to overnight incubation at 42°C in the same solution containing about 5ϫ10 6 cpm/ml 32 P-labeled CYP2B1 cDNA probe. After hybridization, the membrane was washed with 2ϫSSC/0.1% SDS at 42°C for 30 min and with 0.2ϫSSC/0.1% SDS at 42°C for 30 min.
Statistical Analysis Means of values were confirmed using Student's two-tailed t-test. Values were considered significantly different from the controls at pϽ0.05.
RESULTS AND DISCUSSION
Clotrimazole is well known to be potent inducer of rat hepatic P450 among imidazole drugs and chemicals.
1,2,9,30) Recently, we have reported that climbazole is the most powerful inducer of hepatic P450 in female Wistar rats. 20) Based on our previous findings, 20) we first examined whether there are strain differences in the induction of P450 and drug-metabolizing enzyme activities by climbazole in Long-Evans rats because there is little information on the induction response of hepatic enzymes in this strain. No toxic manifestations were observed after treatment with climbazole even at higher dose levels (0.80 mmol/kg). As expected, 20) climbazole slightly increased the P450 content at the lower dose (0.10 mmol/ kg) and significantly induced P450 with increasing dose up to 0.80 mmol/kg in a dose-related manner in both LongEvans and Wistar rats (Fig. 1B) . The results indicate that climbazole produces dose-dependent induction of P450 without strain differences between Wistar 20) and Long-Evans female rats. The effects of climbazole on drug-metabolizing enzyme activities are shown in Fig. 1C . In Long-Evans rats, aminopyrine N-demethylase activity reached the maximum at 0.20 mmol/kg, and then gradually decreased with increasing climbazole dose up to the highest dose examined. At higher dose levels (Ͼ0.60 mmol/kg), climbazole inhibited aminopyrine N-demethylase activity to about 60% of that in the controls. On the other hand, aminopyrine N-demethylase activity reached the maximum at climbazole 0.40 mmol/kg and then gradually decreased with increasing climbazole dose up to the highest dose examined. These results suggest that climbazole induces and inhibits drug-metabolizing enzyme activity in vivo. Erythromycin N-demethylase activity in Long-Evans rats was also examined (data not shown), although, we did not observe the induction of catalytic activity at any dose level. 20) These findings indicate that strain differences exist in the induction of drug-metabolizing enzyme activity by climbazole in the rat liver.
Rodrigues et al. 31) and Hostetler et al. 32) have demonstrated that clotrimazole and miconazole increase the production of CYP2B1/2 and CYP3A subfamilies, but not that of the CYP1A1/2 isozyme. In addition, Sabzevari et al. have revealed that bifonazole induces CYP4A production. 33) CYP2E1 is induced by nitrogen-and sulfur-containing heterocycles. 34) Moreover, diphenylmethylimidazole predominantly induced CYP2B, whereas 1-benzylimidazole increased both CYP2B and 1A species. 12) On the basis of these findings, we examined the effects of climbazole on the induction of various P450 species. Interestingly, climbazole increased CYP2B1 production proportion to the increase in total P450 content up to a dose of 0.40 mmol/kg, although this compound did not produce such marked induction of CYP2B1 at higher dose levels (Table 1) . Climbazole also induced CYP3A2, but failed to induce 2E1 and 2C12 production, irrespective of the marked increase in total P450 content (Fig. 1B) . These findings suggest that climbazole is a specific inducer of the CYP2B1 and 3A2 isoforms.
When the time-course effects of climbazole on hepatic microsomal P450 and drug-metabolizing enzyme activities were examined in Long-Evans rats, a significant increase in P450 content at 24 h to about 2.2-fold of the controls was seen, which gradually returned to the control levels by 96 h (Fig. 2A) . Time-dependent alterations in aminopyrine and erythromycin N-demethylase activities induced by climbazole treatment in Long-Evans rats are shown in Fig. 2B . Climbazole markedly decreased aminopyrine N-demethylase activity when determined at 24 h, but aminopyrine and erythromycin N-demethylase activities maximally increased at 48 h to about 2.5-and 1.8-fold, respectively, of that in controls (Fig. 2B) . Interestingly, climbazole increased aminopyrine N-demethylase activity to a greater extent than erythromycin N-demethylase activity. These results indicate that climbazole induces and inhibits drug-metabolizing enzymes in vivo.
As listed in Table 2 , climbazole failed to induce CYP2B1 production at 24 h later, but then induced it at 48 to 72 h in parallel with the increase in aminopyrine N-demethylase activity. On the other hand, climbazole apparently induced CYP3A2 production at 24 h, at which time erythromycin Ndemethylase activity was slightly increased (Fig. 2B) . Both CYP2B1 and 3A2 isozymes gradually returned to the control levels by 120 h. Climbazole did not influence the levels of CYP2E1 and 2C12 species at various time periods (Table 2) .
Hostetler et al. reported that clotrimazole and miconazole, but not ketoconazole, induce CYP2B1/2 proteins together with the increase of the corresponding mRNAs. 32) Their results indicate that induction of CYP2B species by azole antimycotic drugs is regulated by transcriptional mechanisms. To elucidate the possible mechanism(s) of the induction of CYP2B1 by climbazole, we performed Northern blot analysis of P450 2B1 mRNA (Fig. 3) . Treatment of rats with climbazole resulted in an increase in hybridizable P450 2B1 mRNA, despite the fact that climbazole failed to increase CYP2B1 protein at 24 h ( Table 2 ). The increased P450 2B1 mRNA reached a maximum at 48 h, and then gradually declined to the control levels by 96 h. These results indicate that induction of CYP2B1 by climbazole is accompanied by a significant increase in P450 2B1 mRNA, and suggest that the mechanism of induction of CYP2B1 by climbazole is regulated by transcriptional mechanisms. However, we observed that climbazole stimulated P450 2B1 mRNA synthesis at 24 h after its administration without increasing CYP2B1 protein level (Table 2) . It is not clear at present why such a time course gap in the maximum induced levels occurs between P450 2B1 mRNA synthesis and its product 2B1 protein after climbazole treatment. Climbazole may not inhibit high molecular weight synthesis, because both mRNA and protein synthesis occurred in rat liver treated with this compounds. Dwarki et al. have shown that a decreased heme pool in the liver prevented the induction of CYP2B1/2 translation producible by the prototype CYP2B1/2 inducer phenobarbital. 35) Stilbene compounds, which have also been shown to be inducers of CYP2B1, did not increase the enzyme protein at early time periods because of the induction of heme oxygenase activity. However, we observed that climbazole fails to induce heme oxygenase activity at various time periods (data not shown). Additional studies are required to clarify this point.
Wrighton et al. 36) and Watkins et al. 37) have shown that macrolide antibiotic triacetyloleandomycin (TAO) treatment results in a marked accumulation of CYP3A isozyme with prolongation of the half-life of the protein and a slight increase in P450 3A mRNA. In addition, TAO is known to be converted by P450 3A enzyme to a metabolite that then tightly binds to the enzyme protein and results in the inhibition of the catalytic activity. [36] [37] In studying the drug-metabolizing enzyme activity of N-substituted imidazole compounds, Pershing et al. 9) and Ritter and Franklin 30) reported that high-dose clotrimazole treatment potently induces P450 3A, similar to dexamethasone (high catalytic activity of ery- Control  100  100  100  100  24  97  144  95  100  48  121  111  84  100  72  128  84  96  100  96  118  69  99  91  120  113  65  86  86 Each blot was calculated using Quantity One, and the extent of blots for each P450 isoform is represented as a % of the control. Rats were treated with climbazole at a dose of 0.60 mmol/kg i.p., and killed at the times indicated. For each sample, 20 mg of isolated total RNA was loaded onto 1% agarose/formamide gel, and transferred to a nylon membrane with 20ϫSSPE (3 M NaCl, 173 mM NaH 2 PO 4 , 25 mM EDTA) overnight. Hybridization was done with 32 P-labeled P450 2B1 cDNA as a probe, and autoradiography was done overnight at Ϫ80°C. Other experimental conditions and details are described in Materials and Methods.
thromycin N-demethylation). Climbazole treatment did not result in such a marked increase in erythromycin N-demethylase activity even at the highest dose examined (0.8 mmol/ kg); however, the enzyme activity was increased to about 1.8-fold that of the controls at 48 h (Fig. 2B) . These results suggest that climbazole has properties similar to clotrimazole with respect to the induction of the CYP3A2 isozyme. The occurrence of an optimum time for increasing erythromycin N-demethylase activity following treatment with climbazole is presumably due to a balance between the time for inhibitory factor clearance from P450 protein and the degradation of newly synthesized enzymes. Whether climbazole interrupts the degradation of CYP3A2 protein and results in the accumulation of the protein remains to be determined.
Ritter and Franklin have reported that clotrimazole, tioconazole, and miconazole increase cytosolic glutathione Stransferase and microsomal UDP-glucuronosyl transferase activities. 2, 30) Clotrimazole is a potent inducer of P450 but a weak inducer of conjugation enzymes. 2, 30) On the basis of their findings, we examined the effect of climbazole on phase II enzymes. As illustrated in Table 3 , both glutathione Stransferase and UDP-glucuronosyl transferase activities were increased to about 1.3-and 1.8-fold those in the corresponding controls, respectively, at the climbazole dose of 0.20 mmol/kg. Climbazole did not produce further increases in these enzymes at the higher doses examined. Taking these results together, climazole is a clotrimazole-like inducer of hepatic phase II conjugation enzymes.
In conclusion, this study has shown that climbazole is an inducer of P450 2B1 and 3A2 with strain differences; however, the effect on these P450 species is markedly differentiated in regard to dose level and time period. Specifically, the time-course gap between P450 2B1 mRNA and its product after climbazole administration is likely to be a unique phenomenon. Furthermore, climbazole decreased P450 2B1 and failed to induce P450 3A2, irrespective of the marked increase in total P450 content. At present, it is not clear why strain differences exist in the induction of drug-metabolizing enzyme activity by climbazole at the molecular level.
